Dublin, May 17, 2018 (GLOBE NEWSWIRE) -- The "Global Respiratory Drugs Market 2018-2024" report has been added to ResearchAndMarkets.com's offering.

Respiratory disorders, which affect mechanisms of the respiratory system such as the lungs and airway, are a wide-ranging chronic disease with a diversity of underlying causes, ranging from inherited mutations to pathological inflammation.

The respiratory disorders market is dominated by long-acting beta-agonist (LABA) and long-acting muscarinic antagonist (LAMA) therapies for chronic obstructive pulmonary disease (COPD) and asthma. These drugs stimulate muscles surrounding the bronchial tubes to suppress and open the airways.

Respiratory therapy area consists of signs that affect the lungs, bronchi, trachea, larynx, pharynx and nose in various ways, such as the scarring of lung tissue or the extreme production of mucus. Respiratory disease generally results in breathing difficulties, that can lead to troubles in sleep, wheezing, anxiety, and stress.

During worse condition, shortness of breath (dyspnea) can limit physical activity, affecting both the quality of life and life expectancy of sufferers. The cause of respiratory disorders contrasts significantly across each indication and comprises factors such as environment, occupation, genetic predisposition, and aging.

Report Scope:

Report Category: Pharmacuticals / Healthcare

Therapy Type

• Asthma
• Chronic Obstructive Pulmonary Disease
• Idiopathic Pulmonary Fibrosis
• Cystic Fibrosis

End-user

• Hospitals
• Ambulatory Care
• Others

Key Topics Covered:

1 Industry Outlook
1.1 Industry Overview
1.2 Total Addressable Market
1.3 Industry Trends

2 Report Outline
2.1 Report Scope
2.2 Report Summary
2.3 Research Methodology
2.4 Report Assumptions

3 Market Snapshot
3.1 Market Definition
3.2 Segmented Addressable Market
3.3 Importance Of Respiratory Care
3.4 Trends Of Respiratory Drugs Market
3.5 Related Markets
3.5.1 Oncology (Cancer) Drugs
3.5.2 Active Pharmaceutical Ingredients
3.5.3 Over The Counter Drugs
3.5.4 Diabetes Drugs

4 Market Outline
4.1 Pipeline Products Of Respiratory Drugs By Major Companies
4.2 Market Segmentation
4.3 Porter 5 Forces
4.4 Pest Analysis

5 Market Characteristics
5.1 Market Dynamics Of Respiratory Drugs Market
5.1.1 Drivers
5.1.1.1 Increasing Aging Population
5.1.1.2 Rising Prevalence Of Respiratory Diseases
5.1.1.3 High Prevalence Of Tobacco Smoking
5.1.2 Opportunities
5.1.2.1 Supportive Initiatives From Government And Other Organizations
5.1.2.2 Huge Pool Of Undiagnosed Chronic Obstructive Pulmonary Disease Population
5.1.3 Restraints
5.1.3.1 Expiry Of Patents For Blockbuster Drugs
5.1.3.2 Complex Drug Development Process
5.1.4 DRO - Impact Analysis
5.1.5 Key Stakeholders

6 Application: Market Size And Analysis
6.1 Overview
6.2 Asthma
6.3 Chronic Obstructive Pulmonary Disease (Copd)
6.4 Cystic Fibrosis
6.5 Allergic Rhinitis
6.6 Others

7 Regions: Market Size And Analysis
7.1 Overview
7.2 North America
7.2.1 Overview
7.2.2 United States
7.2.3 Canada
7.3 Europe
7.3.1 Overview
7.3.2 United Kingdom
7.3.3 Germany
7.3.4 France
7.4 Apac
7.4.1 Overview
7.4.2 India
7.4.3 China
7.4.4 Japan
7.5 Rest Of The World
7.5.1 Overview
7.5.2 Middle East
7.5.3 Brazil
7.5.4 Mexico

8 Competitive Landscape

9 Vendor Profiles
9.1 Novartis AG
9.2 Glaxosmithkline Plc
9.3 Astra Zenca Plc
9.4 F.Hoffmann-La Roche Ltd.
9.5 Vertex Pharmaceuticals Inc.

10 Companies To Watch For
10.1 Boehringer Ingelheim GmbH
10.2 Teva Pharmaceutical Industries Ltd.
10.3 Gilead Sciences Inc.
10.4 Bayer AG
10.5 Pfizer Inc.
10.6 Bristol-Myers Squibb Co.
10.7 Merck & Co.
10.8 Sanofi
10.9 Mallinckrodt Plc

For more information about this report visit https://www.researchandmarkets.com/research/xrz4kq/global?w=12